Publications
733
Citations
8,414
Est. group size
~36
Recurring co-author estimate
Active years
53
Publishing since 1974
Eric A. Singer's research focuses on urologic cancers, particularly kidney (renal cell), bladder (urothelial), and prostate cancer, spanning surgical treatment, systemic therapies (like immunotherapy and targeted drugs), and biomarkers for predicting patient outcomes. His work combines clinical trials, outcomes research, and molecular/genomic analyses (such as circulating tumor DNA and gene expression) aimed at improving diagnosis, treatment selection, and disparities in care.
Publication output has grown substantially over the past decade, rising from about 18 papers per year in 2017 to a peak of nearly 200 in 2024, indicating a strongly increasing trend in research activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- A benchmark of expert-level academic questions to assess AI capabilities
Nature · 2026
- Understanding what surgical advanced practice providers want: A survey of autonomy, tasks, and training preferences across three institutions
The American Journal of Surgery · 2026
- Circulating tumor DNA dynamics as a predictive biomarker of response and survival in metastatic urothelial carcinoma treated with enfortumab vedotin and pembrolizumab.
Journal of Clinical Oncology · 2026
- Cyto-KIK: A phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib).
Journal of Clinical Oncology · 2026
- Editorial Comment: Racial and Ethnic Disparities in the Utilization of Partial Nephrectomy and Robotic Surgery for Renal Cell Carcinoma
JU Open Plus · 2026
- Editorial Comment: Current and Emerging Systemic Therapies for Advanced Clear-Cell Renal Cell Carcinoma: A Narrative Review
JU Open Plus · 2026
- A Rare Case of Gluteal Compartment Syndrome and Rhabdomyolysis After Robotic-Assisted Partial Nephrectomy
World Journal of Nephrology and Urology · 2026
- A benchmark of expert-level academic questions to assess AI capabilities
Open Research Online (The Open University) · 2026
- Insulin pathway changes in localized prostate cancer: A multi-institutional analysis.
Journal of Clinical Oncology · 2026
- Incidence of adolescent and young adult renal cell carcinoma in the modern era.
Journal of Clinical Oncology · 2026
- ADC target signatures in urothelial carcinoma: A transcriptomic framework for precision therapy.
Journal of Clinical Oncology · 2026
- Association of enriched <i>YES1</i> tumor expression at the stromal interface with overall survival in clear cell renal cell carcinoma when treated with first-line immune checkpoint blockade.
Journal of Clinical Oncology · 2026
- Outcomes in participants (pts) with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC) who underwent radical cystectomy (RC) after pembrolizumab (pembro): KEYNOTE-057 cohort A post hoc analysis.
Journal of Clinical Oncology · 2026
- A benchmark of expert-level academic questions to assess AI capabilities
RWTH Publications (RWTH Aachen) · 2026
- Abstract B005: Conditional reprogramming models for translational studies in urological cancer
Cancer Research · 2026
- Journal of Clinical Oncology×64
- The Journal of Urology×55
- Urologic Oncology Seminars and Original Investigations×27
- Elsevier eBooks×20
- Urology×14
- Benjamin N. Schmeusser
Medicine · Indiana University
- Chandru P. Sundaram
Medicine · Indiana University
- Taylor Goodstein
Medicine · The Ohio State University
- Megan Hinkley
Medicine · The Ohio State University
- Ronald S. Boris
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile